Boundless Bio, Inc. (NASDAQ: BOLD) Stock Competitors & Peer Comparison
See BOLD's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BOLD and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BOLD | $2.81 | +0.36% | 63.2M | -0.98 | -$2.86 | N/A |
| VRTX | $508.34 | -1.55% | 129B | 26.70 | $19.03 | N/A |
| REGN | $784.85 | -0.58% | 80.9B | 17.20 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $990.32 | -0.55% | 61.6B | 89.38 | $11.08 | N/A |
| MRNA | $154.04 | -2.55% | 61.1B | -18.90 | -$8.15 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $190.95 | -3.04% | 40.6B | -21.64 | -$8.82 | N/A |
| RVMDW | $9.64 | -6.36% | 38.3B | -1.11 | -$8.82 | N/A |
| ONC | $350.84 | -0.74% | 37.5B | 61.77 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
BOLD vs VRTX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, VRTX has a market cap of 129B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while VRTX trades at $508.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas VRTX's P/E ratio is 26.70. In terms of profitability, BOLD's ROE is -0.71%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, BOLD is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
BOLD vs REGN Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, REGN has a market cap of 80.9B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while REGN trades at $784.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas REGN's P/E ratio is 17.20. In terms of profitability, BOLD's ROE is -0.71%, compared to REGN's ROE of +0.14%. Regarding short-term risk, BOLD is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
BOLD vs VRNA Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas VRNA's P/E ratio is -102.80. In terms of profitability, BOLD's ROE is -0.71%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, BOLD is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
BOLD vs ARGX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ARGX has a market cap of 61.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ARGX trades at $990.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ARGX's P/E ratio is 89.38. In terms of profitability, BOLD's ROE is -0.71%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, BOLD is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
BOLD vs MRNA Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, MRNA has a market cap of 61.1B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while MRNA trades at $154.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas MRNA's P/E ratio is -18.90. In terms of profitability, BOLD's ROE is -0.71%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, BOLD is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check MRNA's competition here
Seagen Inc. (NASDAQ: SGEN)
BOLD vs SGEN Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BOLD's ROE is -0.71%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BOLD is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
BOLD vs RVMD Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, RVMD has a market cap of 40.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while RVMD trades at $190.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas RVMD's P/E ratio is -21.64. In terms of profitability, BOLD's ROE is -0.71%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, BOLD is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
BOLD vs RVMDW Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, RVMDW has a market cap of 38.3B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while RVMDW trades at $9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas RVMDW's P/E ratio is -1.11. In terms of profitability, BOLD's ROE is -0.71%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, BOLD is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
BOLD vs ONC Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ONC has a market cap of 37.5B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ONC trades at $350.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ONC's P/E ratio is 61.77. In terms of profitability, BOLD's ROE is -0.71%, compared to ONC's ROE of +0.14%. Regarding short-term risk, BOLD is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
BOLD vs ALNY Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ALNY has a market cap of 32.9B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ALNY trades at $239.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ALNY's P/E ratio is 44.24. In terms of profitability, BOLD's ROE is -0.71%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, BOLD is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
BOLD vs ROIV Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ROIV has a market cap of 28.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ROIV trades at $39.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ROIV's P/E ratio is -37.84. In terms of profitability, BOLD's ROE is -0.71%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, BOLD is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
BOLD vs INSM Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, INSM has a market cap of 26B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while INSM trades at $120.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas INSM's P/E ratio is -29.20. In terms of profitability, BOLD's ROE is -0.71%, compared to INSM's ROE of -1.11%. Regarding short-term risk, BOLD is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
BOLD vs INCY Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, INCY has a market cap of 25.4B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while INCY trades at $125.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas INCY's P/E ratio is 16.84. In terms of profitability, BOLD's ROE is -0.71%, compared to INCY's ROE of +0.30%. Regarding short-term risk, BOLD is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
BOLD vs BNTX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, BNTX has a market cap of 24.1B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while BNTX trades at $96.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas BNTX's P/E ratio is -12.46. In terms of profitability, BOLD's ROE is -0.71%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, BOLD is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check BNTX's competition here
Genmab A/S (NASDAQ: GMAB)
BOLD vs GMAB Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while GMAB trades at $34.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas GMAB's P/E ratio is 26.18. In terms of profitability, BOLD's ROE is -0.71%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, BOLD is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
BOLD vs UTHR Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, UTHR has a market cap of 21B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while UTHR trades at $494.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas UTHR's P/E ratio is 17.70. In terms of profitability, BOLD's ROE is -0.71%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, BOLD is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
BOLD vs BGNE Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas BGNE's P/E ratio is -22.55. In terms of profitability, BOLD's ROE is -0.71%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, BOLD is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
BOLD vs DNA-WT Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BOLD's ROE is -0.71%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, BOLD is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
BOLD vs JAZZ Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while JAZZ trades at $240.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas JAZZ's P/E ratio is 8.98. In terms of profitability, BOLD's ROE is -0.71%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, BOLD is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
BOLD vs NBIX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, NBIX has a market cap of 14.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while NBIX trades at $146.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas NBIX's P/E ratio is 21.13. In terms of profitability, BOLD's ROE is -0.71%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, BOLD is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
BOLD vs ASND Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ASND has a market cap of 14.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ASND trades at $236.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ASND's P/E ratio is -97.82. In terms of profitability, BOLD's ROE is -0.71%, compared to ASND's ROE of +1.90%. Regarding short-term risk, BOLD is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
BOLD vs EXEL Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, EXEL has a market cap of 14.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while EXEL trades at $58.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas EXEL's P/E ratio is 16.67. In terms of profitability, BOLD's ROE is -0.71%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, BOLD is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
BOLD vs SMMT Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, SMMT has a market cap of 14.2B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while SMMT trades at $17.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas SMMT's P/E ratio is -15.94. In terms of profitability, BOLD's ROE is -0.71%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, BOLD is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
BOLD vs HALO Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, HALO has a market cap of 13.3B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while HALO trades at $112.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas HALO's P/E ratio is 20.98. In terms of profitability, BOLD's ROE is -0.71%, compared to HALO's ROE of +1.81%. Regarding short-term risk, BOLD is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
BOLD vs BBIO Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while BBIO trades at $66.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas BBIO's P/E ratio is -17.81. In terms of profitability, BOLD's ROE is -0.71%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, BOLD is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
BOLD vs KRTX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BOLD's ROE is -0.71%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BOLD is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
BOLD vs BMRN Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while BMRN trades at $63.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas BMRN's P/E ratio is 30.74. In terms of profitability, BOLD's ROE is -0.71%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, BOLD is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
BOLD vs MDGL Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, MDGL has a market cap of 12.3B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while MDGL trades at $531.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas MDGL's P/E ratio is -41.52. In terms of profitability, BOLD's ROE is -0.71%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, BOLD is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
BOLD vs TECH Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while TECH trades at $72.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas TECH's P/E ratio is 37.30. In terms of profitability, BOLD's ROE is -0.71%, compared to TECH's ROE of +0.09%. Regarding short-term risk, BOLD is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
BOLD vs RNAM Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas RNAM's P/E ratio is -17.39. In terms of profitability, BOLD's ROE is -0.71%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, BOLD is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
BOLD vs AXSM Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while AXSM trades at $207.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas AXSM's P/E ratio is -54.25. In terms of profitability, BOLD's ROE is -0.71%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, BOLD is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check AXSM's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
BOLD vs TWST Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, TWST has a market cap of 10.4B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while TWST trades at $166.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas TWST's P/E ratio is -75.22. In terms of profitability, BOLD's ROE is -0.71%, compared to TWST's ROE of -0.30%. Regarding short-term risk, BOLD is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check TWST's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
BOLD vs KRYS Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while KRYS trades at $336.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas KRYS's P/E ratio is 42.19. In terms of profitability, BOLD's ROE is -0.71%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, BOLD is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check KRYS's competition here
10x Genomics, Inc. (NASDAQ: TXG)
BOLD vs TXG Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, TXG has a market cap of 9.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while TXG trades at $76.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas TXG's P/E ratio is -129.83. In terms of profitability, BOLD's ROE is -0.71%, compared to TXG's ROE of -0.09%. Regarding short-term risk, BOLD is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check TXG's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
BOLD vs KYMR Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while KYMR trades at $117.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas KYMR's P/E ratio is -36.80. In terms of profitability, BOLD's ROE is -0.71%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, BOLD is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
BOLD vs RXDX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BOLD's ROE is -0.71%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BOLD is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check RXDX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
BOLD vs ARWR Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ARWR has a market cap of 9.4B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ARWR trades at $66.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ARWR's P/E ratio is -29.55. In terms of profitability, BOLD's ROE is -0.71%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, BOLD is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ARWR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
BOLD vs PTGX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, PTGX has a market cap of 9.2B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while PTGX trades at $143.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas PTGX's P/E ratio is 138.83. In terms of profitability, BOLD's ROE is -0.71%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, BOLD is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
BOLD vs NUVL Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas NUVL's P/E ratio is -21.79. In terms of profitability, BOLD's ROE is -0.71%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, BOLD is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
BOLD vs CRNX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas CRNX's P/E ratio is -16.86. In terms of profitability, BOLD's ROE is -0.71%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, BOLD is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check CRNX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
BOLD vs IBRX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while IBRX trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas IBRX's P/E ratio is -8.74. In terms of profitability, BOLD's ROE is -0.71%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, BOLD is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check IBRX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
BOLD vs IMGN Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BOLD's ROE is -0.71%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, BOLD is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check IMGN's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
BOLD vs TGTX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, TGTX has a market cap of 8.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while TGTX trades at $56.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas TGTX's P/E ratio is 20.61. In terms of profitability, BOLD's ROE is -0.71%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, BOLD is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check TGTX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
BOLD vs CYTK Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, CYTK has a market cap of 8.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while CYTK trades at $68.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas CYTK's P/E ratio is -9.53. In terms of profitability, BOLD's ROE is -0.71%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, BOLD is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check CYTK's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
BOLD vs CAI Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, CAI has a market cap of 8.5B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while CAI trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas CAI's P/E ratio is 84.24. In terms of profitability, BOLD's ROE is -0.71%, compared to CAI's ROE of +0.19%. Regarding short-term risk, BOLD is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check CAI's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
BOLD vs PCVX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, PCVX has a market cap of 8.4B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while PCVX trades at $58.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas PCVX's P/E ratio is -7.62. In terms of profitability, BOLD's ROE is -0.71%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, BOLD is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check PCVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
BOLD vs BPMC Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BOLD's ROE is -0.71%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, BOLD is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
BOLD vs APGE Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas APGE's P/E ratio is -31.19. In terms of profitability, BOLD's ROE is -0.71%, compared to APGE's ROE of -0.30%. Regarding short-term risk, BOLD is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check APGE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
BOLD vs PRAX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while PRAX trades at $298.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas PRAX's P/E ratio is -23.12. In terms of profitability, BOLD's ROE is -0.71%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, BOLD is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
BOLD vs CERE Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas CERE's P/E ratio is -16.47. In terms of profitability, BOLD's ROE is -0.71%, compared to CERE's ROE of -0.72%. Regarding short-term risk, BOLD is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
BOLD vs SYRE Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, SYRE has a market cap of 7.8B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while SYRE trades at $90.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas SYRE's P/E ratio is -46.28. In terms of profitability, BOLD's ROE is -0.71%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, BOLD is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check SYRE's competition here
Abivax S.A. (NASDAQ: ABVX)
BOLD vs ABVX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ABVX has a market cap of 7.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ABVX trades at $105.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ABVX's P/E ratio is -55.06. In terms of profitability, BOLD's ROE is -0.71%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, BOLD is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ABVX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
BOLD vs IMVT Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, IMVT has a market cap of 7.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while IMVT trades at $36.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas IMVT's P/E ratio is -13.10. In terms of profitability, BOLD's ROE is -0.71%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, BOLD is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check IMVT's competition here
Metsera, Inc. (NASDAQ: MTSR)
BOLD vs MTSR Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas MTSR's P/E ratio is -23.58. In terms of profitability, BOLD's ROE is -0.71%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, BOLD is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
BOLD vs IONS Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while IONS trades at $44.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas IONS's P/E ratio is -25.84. In terms of profitability, BOLD's ROE is -0.71%, compared to IONS's ROE of -1.11%. Regarding short-term risk, BOLD is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check IONS's competition here
Belite Bio, Inc (NASDAQ: BLTE)
BOLD vs BLTE Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, BLTE has a market cap of 6.9B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while BLTE trades at $170.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas BLTE's P/E ratio is -91.42. In terms of profitability, BOLD's ROE is -0.71%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, BOLD is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check BLTE's competition here
Merus N.V. (NASDAQ: MRUS)
BOLD vs MRUS Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas MRUS's P/E ratio is -17.05. In terms of profitability, BOLD's ROE is -0.71%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, BOLD is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
BOLD vs ACLX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ACLX's P/E ratio is -28.27. In terms of profitability, BOLD's ROE is -0.71%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, BOLD is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ACLX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
BOLD vs RYTM Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, RYTM has a market cap of 6.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while RYTM trades at $97.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas RYTM's P/E ratio is -31.42. In terms of profitability, BOLD's ROE is -0.71%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, BOLD is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check RYTM's competition here
CG Oncology Inc. (NASDAQ: CGON)
BOLD vs CGON Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while CGON trades at $74.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas CGON's P/E ratio is -27.74. In terms of profitability, BOLD's ROE is -0.71%, compared to CGON's ROE of -0.25%. Regarding short-term risk, BOLD is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check CGON's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
BOLD vs RETA Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas RETA's P/E ratio is -66.29. In terms of profitability, BOLD's ROE is -0.71%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BOLD is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
BOLD vs CNTA Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas CNTA's P/E ratio is -22.63. In terms of profitability, BOLD's ROE is -0.71%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, BOLD is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
BOLD vs TVTX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while TVTX trades at $62.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas TVTX's P/E ratio is -139.47. In terms of profitability, BOLD's ROE is -0.71%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, BOLD is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check TVTX's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
BOLD vs ORKA Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ORKA has a market cap of 5.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ORKA trades at $94.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ORKA's P/E ratio is -48.95. In terms of profitability, BOLD's ROE is -0.71%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, BOLD is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check ORKA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
BOLD vs LGND Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, LGND has a market cap of 5.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while LGND trades at $283.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas LGND's P/E ratio is 31.12. In terms of profitability, BOLD's ROE is -0.71%, compared to LGND's ROE of +0.20%. Regarding short-term risk, BOLD is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
BOLD vs CDTX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas CDTX's P/E ratio is -19.77. In terms of profitability, BOLD's ROE is -0.71%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, BOLD is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check CDTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
BOLD vs MIRM Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while MIRM trades at $91.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas MIRM's P/E ratio is -6.31. In terms of profitability, BOLD's ROE is -0.71%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, BOLD is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check MIRM's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
BOLD vs SRRK Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, SRRK has a market cap of 5.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while SRRK trades at $46.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas SRRK's P/E ratio is -13.52. In terms of profitability, BOLD's ROE is -0.71%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, BOLD is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check SRRK's competition here
Abcam plc (NASDAQ: ABCM)
BOLD vs ABCM Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BOLD's ROE is -0.71%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BOLD is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
BOLD vs ISEE Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BOLD's ROE is -0.71%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BOLD is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ISEE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
BOLD vs PTCT Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while PTCT trades at $65.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas PTCT's P/E ratio is -28.06. In terms of profitability, BOLD's ROE is -0.71%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, BOLD is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check PTCT's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
BOLD vs CRSP Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, CRSP has a market cap of 5.5B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while CRSP trades at $56.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas CRSP's P/E ratio is -11.88. In terms of profitability, BOLD's ROE is -0.71%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, BOLD is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check CRSP's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
BOLD vs DNTH Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while DNTH trades at $96.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas DNTH's P/E ratio is -23.33. In terms of profitability, BOLD's ROE is -0.71%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, BOLD is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
BOLD vs COGT Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while COGT trades at $31.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas COGT's P/E ratio is -14.93. In terms of profitability, BOLD's ROE is -0.71%, compared to COGT's ROE of -0.73%. Regarding short-term risk, BOLD is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check COGT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
BOLD vs APLS Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas APLS's P/E ratio is 38.35. In terms of profitability, BOLD's ROE is -0.71%, compared to APLS's ROE of +0.40%. Regarding short-term risk, BOLD is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check APLS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
BOLD vs DFTX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while DFTX trades at $38.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas DFTX's P/E ratio is N/A. In terms of profitability, BOLD's ROE is -0.71%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, BOLD is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check DFTX's competition here
Erasca, Inc. (NASDAQ: ERAS)
BOLD vs ERAS Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ERAS trades at $14.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ERAS's P/E ratio is -15.88. In terms of profitability, BOLD's ROE is -0.71%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, BOLD is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check ERAS's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
BOLD vs EWTX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while EWTX trades at $45.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas EWTX's P/E ratio is -24.50. In terms of profitability, BOLD's ROE is -0.71%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, BOLD is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
BOLD vs PBLS Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, PBLS has a market cap of 4.9B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while PBLS trades at $41.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas PBLS's P/E ratio is -47.42. In terms of profitability, BOLD's ROE is -0.71%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, BOLD is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check PBLS's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
BOLD vs TERN Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas TERN's P/E ratio is -51.41. In terms of profitability, BOLD's ROE is -0.71%, compared to TERN's ROE of -0.20%. Regarding short-term risk, BOLD is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check TERN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
BOLD vs ACAD Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ACAD has a market cap of 4.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ACAD trades at $27.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ACAD's P/E ratio is 12.29. In terms of profitability, BOLD's ROE is -0.71%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, BOLD is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ACAD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
BOLD vs IOVA Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, IOVA has a market cap of 4.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while IOVA trades at $10.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas IOVA's P/E ratio is -14.04. In terms of profitability, BOLD's ROE is -0.71%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, BOLD is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check IOVA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
BOLD vs ADPT Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ADPT has a market cap of 4.6B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ADPT trades at $28.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ADPT's P/E ratio is -69.63. In terms of profitability, BOLD's ROE is -0.71%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, BOLD is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
BOLD vs FOLD Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas FOLD's P/E ratio is -161.00. In terms of profitability, BOLD's ROE is -0.71%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, BOLD is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
BOLD vs AKRO Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas AKRO's P/E ratio is -14.57. In terms of profitability, BOLD's ROE is -0.71%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, BOLD is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
BOLD vs ALPN Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BOLD's ROE is -0.71%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, BOLD is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check ALPN's competition here
Veradermics, Incorporated (NYSE: MANE)
BOLD vs MANE Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, MANE has a market cap of 4.5B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while MANE trades at $106.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas MANE's P/E ratio is -33.96. In terms of profitability, BOLD's ROE is -0.71%, compared to MANE's ROE of -0.38%. Regarding short-term risk, BOLD is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check MANE's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
BOLD vs TLX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, TLX has a market cap of 4.3B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while TLX trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas TLX's P/E ratio is 131.42. In terms of profitability, BOLD's ROE is -0.71%, compared to TLX's ROE of +0.07%. Regarding short-term risk, BOLD is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check TLX's competition here
Opthea Limited (NASDAQ: OPT)
BOLD vs OPT Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas OPT's P/E ratio is -1.52. In terms of profitability, BOLD's ROE is -0.71%, compared to OPT's ROE of +1.18%. Regarding short-term risk, BOLD is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
BOLD vs PRTC Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas PRTC's P/E ratio is -3.78. In terms of profitability, BOLD's ROE is -0.71%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, BOLD is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check PRTC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
BOLD vs RLAY Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while RLAY trades at $18.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas RLAY's P/E ratio is -12.00. In terms of profitability, BOLD's ROE is -0.71%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, BOLD is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check RLAY's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
BOLD vs MRTX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BOLD's ROE is -0.71%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BOLD is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
BOLD vs CELC Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while CELC trades at $80.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas CELC's P/E ratio is -18.75. In terms of profitability, BOLD's ROE is -0.71%, compared to CELC's ROE of -3.51%. Regarding short-term risk, BOLD is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check CELC's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
BOLD vs ABCL Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while ABCL trades at $12.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas ABCL's P/E ratio is -23.39. In terms of profitability, BOLD's ROE is -0.71%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, BOLD is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
BOLD vs CPRX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas CPRX's P/E ratio is 12.30. In terms of profitability, BOLD's ROE is -0.71%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, BOLD is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check CPRX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
BOLD vs XENE Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while XENE trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas XENE's P/E ratio is -8.46. In terms of profitability, BOLD's ROE is -0.71%, compared to XENE's ROE of -0.44%. Regarding short-term risk, BOLD is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check XENE's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
BOLD vs AMLX Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, AMLX has a market cap of 3.8B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while AMLX trades at $32.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas AMLX's P/E ratio is -22.63. In terms of profitability, BOLD's ROE is -0.71%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, BOLD is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for BOLD.Check AMLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
BOLD vs RYZB Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BOLD's ROE is -0.71%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BOLD is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
BOLD vs CBAY Comparison September 2026
Boundless Bio, Inc. (NASDAQ: BOLD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BOLD stands at 63.2M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BOLD is priced at $2.81 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BOLD currently has a P/E ratio of -0.98, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BOLD's ROE is -0.71%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BOLD is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for BOLD.Check CBAY's competition here